Accelerator Corporation, a privately held Seattle-based biotechnology investment firm, has secured $22.5 million in new venture capital commitments to help it fund emerging biotechnology companies.
 
Accelerator, which employs a venture capital-cum-incubator model to nurture early-stage biotech companies, expects to use the new commitments to fund as many as six companies in the next two to three years, with a particular eye toward university spinouts, executives from the company said last week.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.